First Long-term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients With Colorectal Liver Metastases
Henrik Petrowsky,Michael Linecker,Dimitri A Raptis,Christoph Kuemmerli,Ralph Fritsch,Onur E Kirimker,Deniz Balci,Francesca Ratti,Luca Aldrighetti,Sergey Voskanyan,Federico Tomassini,Roberto I Troisi,Jan Bednarsch,Georg Lurje,Mohammad-Hossein Fard-Aghaie,Tim Reese,Karl J Oldhafer,Omid Ghamarnejad,Arianeb Mehrabi,Mauro E Tun Abraham,Stéphanie Truant,Francois-René Pruvot,Emir Hoti,Patryk Kambakamba,Ivan Capobianco,Silvio Nadalin,Eduardo S M Fernandes,Philipp Kron,Peter Lodge,Pim B Olthof,Thomas van Gulik,Carlos Castro-Benitez,René Adam,Marcel Autran Machado,Martin Teutsch,Jun Li,Marcus N Scherer,Hans J Schlitt,Victoria Ardiles,Eduardo de Santibañes,Roberto Brusadin,Victor Lopez-Lopez,Ricardo Robles-Campos,Massimo Malagó,Roberto Hernandez-Alejandro,Pierre-Alain Clavien,Dimitri A. Raptis,Onur E. Kirimker,Roberto I. Troisi,Karl J. Oldhafer,Mauro E. Tun Abraham,Eduardo S. M. Fernandes,Pim B. Olthof,Marcus N. Scherer,Hans J. Schlitt
DOI: https://doi.org/10.1097/sla.0000000000004330
IF: 13.787
2020-08-21
Annals of Surgery
Abstract:OBJECTIVES: To analyze long-term oncological outcome along with prognostic risk factors in a large cohort of patients with colorectal liver metastases (CRLM) undergoing ALPPS.BACKGROUND: ALPPS is a two-stage hepatectomy variant that increases resection rates and R0 resection rates in patients with primarily unresectable CRLM as evidenced in a recent randomized controlled trial. Long-term oncologic results, however, are lacking.METHODS: Cases in- and outside the International ALPPS Registry were collected and completed by direct contacts to ALPPS centers to secure a comprehensive cohort. Overall, cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with independent risk factors using Cox-regression analysis.RESULTS: The cohort included 510 patients from 22 ALPPS centers over a 10-year period. Ninety-day mortality was 4.9% and median overall survival, CSS, and RFS were 39, 42, and 15 months, respectively. The median follow-up time was 38 months (95% confidence interval 32-43 months). Multivariate analysis identified tumor-characteristics (primary T4, right colon), biological features (K/N-RAS status), and response to chemotherapy (Response Evaluation Criteria in Solid Tumors) as independent predictors of CSS. Traditional factors such as size of metastases, uni versus bilobar involvement, and liver-first approach were not predictive. When hepatic recurrences after ALPPS was amenable to surgical/ablative treatment, median CSS was significantly superior compared to chemotherapy alone (56 vs 30 months, P < 0.001).CONCLUSIONS: This large cohort provides the first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low perioperative mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor biology and good response to chemotherapy.
surgery